Pill form of semaglutide fails to slow Alzheimer’s in large trial

A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer’s disease, drugmaker Novo Nordisk announced on Nov. 24.

This post was originally published on this site